Spotlight on: ESMO 2025


From the congress floor: ESMO 2025 in review

October 17-21, 2025 | Berlin, Germany


The European Society for Medical Oncology (ESMO) 2025 will take place 17th to 21st October in Berlin, Germany. The Congress provides a comprehensive educational and scientific programme that seeks to foster exchange and debate of translational cancer science, showcase first announcements of potentially practice changing data, and stimulate multidisciplinary discussions to improve treatment options for patients.

Covering the Congress onsite at Messe Berlin, pharmaphorum will be interviewing experts in their field and reporting from the broad oncological programme of presentations itself. Key areas of focus this year will include: prevention, screening, and early diagnosis of cancer; the latest breakthroughs in basic science, and translational and clinical cancer research; clinical perspectives of the scientific advances in cancer biology, diagnostics, and new treatments; and the optimal roles of novel diagnostics and treatments for patients with cancer.

This “Spotlight On” page will act as your hub for updates from Berlin over the 17th to 21st October, as well as post-event content, also. Check in here for key takeaways, video and audio content captured live from the Congress floor, and new and write-ups on breaking data releases.

Stay tuned for pharmaphorum’s reporting from one of the most impactful events on the oncology calendar – featuring voices from across the field and reflections on what the latest findings mean for the future of cancer care.

Oncology
ESMO opening press conference

ESMO 2025 commences: ADCs, AI, and Asia

ESMO 2025 has kicked off, with an opening press conference focused on early setting ADCs, the potential of AI in oncology, and new drugs from Asia.

Nicole Raleigh

Reported by Nicole Raleigh

Nicole Raleigh is pharmaphorum’s web editor. Transitioning to the healthcare sector in the last few years, she is an experienced media and communications professional who has worked in print and digital for over 20 years.

Highlights from the past ESMO conferences

Oncology
Dr Meredith McKean interview with Nicole Raleigh

ESMO 2024 – Dr Meredith McKean

In our final video from ESMO 2024, web editor Nicole Raleigh spoke with Dr Meredith McKean, a melanoma investigator at the Sarah Cannon Research Institute.

Oncology
ESMO 2024 Dr Magda Meissner interview with Nicole Raleigh

ESMO 2024 – Magda Meissner

In our penultimate video from ESMO 2024, pharmaphorum spoke with Dr Magda Meissner, consultant medical oncologist at the Velindre Cancer Centre and project lead for QuicDNA, about how a sim

Oncology
Nicole Raleigh interview with Daejin Abidoye at ESMO 2024

ESMO 2024 - Daejin Abidoye

At ESMO 2024, AbbVie presented new data across their solid tumour pipeline, displaying the company’s potential as an emerging leader in solid tumours.

Oncology
Henar Hevia & Carolyn Sousa interview with Nicole Raleigh

ESMO 2024 - Henar Hevia & Carolyn Sousa

ESMO 2024 was chock full of oncological data, diverse presentations providing hope across the cancer spectrum from breast and lung to unmet needs in colorectal and bladder.

Oncology
Israel Lowy from Regeneron interview with Nicole Raleigh

ESMO 2024 - Israel (Izzy) Lowy

ESMO 2024, which followed hot on the heels of this year’s World Conference on Lung Cancer, was abuzz with data around PD-1 inhibitors, LAG-3 inhibitors, and the possibilities for using exis

Oncology
Sven Schaffer and Nicole Raleigh interview at ESMO

ESMO 2024 - Sven Schaffer

The European Society for Medical Oncology (ESMO) 2024 meeting was a well-attended affair at the sprawling Fira Gran Via centre in Barcelona.

News
36272425334_e8631c65f0_z

ESMO 2017 round up: BMS and AZ bounce back

Europe’s biggest cancer congress ESMO wraps up today, having delivering its fair share of major studies and talking points in cancer treatment over five days.

Views & Analysis
iStock 5380328781

Innovations in cancer drug research

While cancer continues to be one of the leading causes of death and illness, new technology and increasing use of real-world data have the potential to revolutionise care.

About ESMO

Founded in 1975, ESMO is a leading global organisation in oncology, rooted in Europe and representing over 45,000 members worldwide. It serves as a central hub for education, professional development, and integrated cancer care, connecting a diverse community of oncology professionals.

ESMO 2025 will spotlight groundbreaking discoveries and cutting-edge treatments, offering a dynamic space to learn from internationally recognised experts, engage in thought-provoking discussions, and connect with peers driving progress in diagnosis, treatment, and survivorship.